文献速递临床试验与 GCP

三氧化二砷联合全反式维甲酸治疗全风险组急性早幼粒细胞白血病:随机对照试验研究方案

Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-09-05

本方案为多中心随机对照试验,比较全风险组急性早幼粒细胞白血病患者接受三氧化二砷联合全反式维甲酸(ATRA-ATO)方案与ATRA-ATO联合化疗方案的疗效。实验组在高危患者巩固和维持治疗中加用甘露醇以促进ATO透过血脑屏障,诱导治疗出现白细胞增多时使用羟基脲。试验注册于中国临床试验注册中心(ChiCTR-IPR-15006821)。

要点

  • 全风险组APL患者随机接受ATRA-ATO或ATRA-ATO联合化疗方案。
  • 高危患者巩固和维持治疗中ATO联合甘露醇以促进透过血脑屏障。
  • 诱导治疗出现白细胞增多时使用羟基脲。

核心结论

  • 本试验旨在比较ATRA-ATO方案与ATRA-ATO联合化疗方案在全风险组APL患者中的疗效。

研究设计与样本

  • 多中心随机对照试验,APL患者随机分为ATRA-ATO组(实验组)和ATRA-ATO联合化疗组(对照组)。

关键数值与推荐

  • 实验组接受ATRA-ATO诱导、巩固和维持治疗,高危患者巩固和维持治疗中ATO联合甘露醇。
  • 诱导治疗出现白细胞增多时使用羟基脲。
  • 对照组接受ATRA-ATO联合化疗进行诱导和巩固治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The treatment of acute promyelocytic leukemia (APL) has been revolutionized in the past two decades by the advent of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). It suggests that non-high-risk APL patients can be cured without chemotherapy. However, ATRA plus chemotherapy is still the standard therapy for the high-risk patients. Central nervous system (CNS) relapse remains a significant cause of treatment failure in high-risk patients. However, increasing the ATO concentration in cerebrospinal fluid (CSF) may reduce CNS relapse in high-risk patients. Mannitol can allow ATO to penetrate the blood-brain barrier (BBB) and reach therapeutically effective levels in the CSF. It is used for the treatment of CNS relapse in patients APL. We compare ATRA-ATO with ATRA-ATO plus chemotherapy in both high-risk and non-high-risk patients with APL. METHODS: This study was designed as a multicenter randomized controlled trial. Patients with APL were randomly assigned into two groups: the ATRA-ATO group (experimental group) and the ATRA-ATO plus chemotherapy group (control group). The experimental group receives therapy with ATRA-ATO for induction, consolidation and maintenance therapy. In the high-risk patients, mannitol will be used with ATO in the consolidation and maintenance therapy. Hydroxyurea will be used in patients who developed leukocytosis in the induction therapy. The control group receives therapy with ATRA-ATO plus chemotherapy for induction and consolidation therapy. DISCUSSION: In this study, a randomized clinical trial design is described. It aims to compare the efficacy of ATRA-ATO versus ATRA-ATO plus chemotherapy in all-risk patients with APL. TRIAL REGISTRATION: Chinese Clinical Trials Registry, ID: ChiCTR-IPR- 15006821 . Registered on 27 July 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhang X, Zhang H, Chen L, et al. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial. Trials. 2018. PMID: 30185214. doi:10.1186/s13063-018-2812-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。